– Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment – “Today's approval reflects our ...

A new treatment appears to reduce food allergies in children and teens, according to interim clinical trial results. A lab-made monoclonal antibody called omalizumab (Xolair) significantly increased ...

– If approved, Xolair self-administration would offer a more flexible option to help select patients manage their treatment needs – – Filing acceptance is based on the well-established efficacy and ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a self-injectable formulation of Xolair for appropriate patients with moderate to severe ...

EAST HANOVER, N.J., April 12, 2021 /PRNewswire/ — Novartis today announced that the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application for Xolair (R) ...

Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted, under ...

A new drug could let those with severe food allergies breathe a sigh of relief. Xolair, or omalizumab, was granted priority review by the Food and Drug Administration on Tuesday for its use in ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...

Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate ...